Arthritis drug shows RSV-fighting potential in lab study, but clinical use remains distant

RSV is the leading cause of infant hospitalization in the U.S., with babies under 6 months and adults over 65 at highest risk of severe disease and death.

Respiratory syncytial virus remains the leading cause of infant hospitalization in the United States, yet no antiviral treatment exists for those already infected. A new laboratory study suggests that indomethacin, an inexpensive arthritis drug with decades of clinical history, may interfere with RSV's ability to replicate inside human respiratory cells — a finding that, while preliminary, opens a door long considered closed. Science moves carefully from petri dish to patient, and experts remind us that promising beginnings do not always become cures, but in a disease without treatment options

Arthritis drug shows RSV-fighting potential in lab study, but clinical use remains distant

Cobertura Relacionada

Receba o Register no seu e-mail